GoAI
Get started
Twist Bioscience Corporation logo

Twist Bioscience Corporation

TWST

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$145.59

+$9.26 · +6.79%

Aug 21, 4:00 PM ET

TWST company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

62

Undervalued

Momentum

70

Gaining

Sentiment

45

Mixed

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Emily Marine Leproust
Listed since
Oct 31, 2018
Employees
979

Market position

Day range

Current $145.59

52-week range

Current $145.59

Open
$138.5
Previous close
$136.33
Volume
1.8M
1.05× average
Average volume
1.71M
Average daily volume
Market cap
9.07B USD
Beta
2.16
Market reference 1
50-day average
$99.9636
+45.64% above average
200-day average
$59.2922
+145.55% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.64B USD
P/E (TTM)
-65.58×
P/B (TTM)
20.38×
P/S (TTM)
21×
EV / EBITDA
-31.43×
Earnings yield
-4.61%
Free cash flow yield
-4.49%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
51.97%
Operating margin
-31.91%
Net margin
-31.66%
Return on equity
-16.42%
Return on assets
-12.10%
Return on invested capital
-24.15%

Financial health

Debt / equity
0.21×
Current ratio
3.64×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends67%1%-66%-132%Gross margin, FY2021: 39.08%Gross margin, FY2022: 41.38%Gross margin, FY2023: 36.61%Gross margin, FY2024: 42.61%Gross margin, FY2025: 50.72%Operating margin, FY2021: -115.41%Operating margin, FY2022: -115.33%Operating margin, FY2023: -88.60%Operating margin, FY2024: -70.56%Operating margin, FY2025: -36.18%Net margin, FY2021: -114.94%Net margin, FY2022: -107.02%Net margin, FY2023: -83.48%Net margin, FY2024: -66.69%Net margin, FY2025: -20.63%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 39.08%. Gross margin FY2022 41.38%. Gross margin FY2023 36.61%. Gross margin FY2024 42.61%. Gross margin FY2025 50.72%. Operating margin FY2021 -115.41%. Operating margin FY2022 -115.33%. Operating margin FY2023 -88.60%. Operating margin FY2024 -70.56%. Operating margin FY2025 -36.18%. Net margin FY2021 -114.94%. Net margin FY2022 -107.02%. Net margin FY2023 -83.48%. Net margin FY2024 -66.69%. Net margin FY2025 -20.63%.

Income trends

Revenue

376.57M USD+20.32%

Operating income

−136.26M USD+38.30%

Net income

−77.67M USD+62.79%
Income trends across reported periods437.71M USD193.17M USD−51.37M USD−295.91M USDRevenue, FY2021: 132.33M USDRevenue, FY2022: 203.57M USDRevenue, FY2023: 245.11M USDRevenue, FY2024: 312.97M USDRevenue, FY2025: 376.57M USDOperating income, FY2021: −152.73M USDOperating income, FY2022: −234.78M USDOperating income, FY2023: −217.16M USDOperating income, FY2024: −220.83M USDOperating income, FY2025: −136.26M USDNet income, FY2021: −152.1M USDNet income, FY2022: −217.86M USDNet income, FY2023: −204.62M USDNet income, FY2024: −208.73M USDNet income, FY2025: −77.67M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 132.33M USD. Revenue FY2022 203.57M USD. Revenue FY2023 245.11M USD. Revenue FY2024 312.97M USD. Revenue FY2025 376.57M USD. Operating income FY2021 −152.73M USD. Operating income FY2022 −234.78M USD. Operating income FY2023 −217.16M USD. Operating income FY2024 −220.83M USD. Operating income FY2025 −136.26M USD. Net income FY2021 −152.1M USD. Net income FY2022 −217.86M USD. Net income FY2023 −204.62M USD. Net income FY2024 −208.73M USD. Net income FY2025 −77.67M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue376.57M USD312.97M USD245.11M USD203.57M USD132.33M USD
Cost of goods sold185.57M USD179.63M USD155.38M USD119.33M USD80.62M USD
Gross profit191M USD133.35M USD89.73M USD84.24M USD51.71M USD
Research and development80.29M USD90.85M USD106.89M USD120.31M USD69.07M USD
Selling, general, and administrative246.98M USD218.4M USD189.74M USD212.95M USD135.9M USD
Operating expenses327.26M USD354.18M USD306.89M USD319.01M USD204.44M USD
Interest income11.36M USD15.34M USD14.37M USD3.06M USD435K USD
Interest expense—29K USD5K USD80K USD367K USD
Depreciation and amortization24.85M USD31.43M USD29.31M USD16.51M USD9.75M USD
Operating income−136.26M USD−220.83M USD−217.16M USD−234.78M USD−152.73M USD
Net income−77.67M USD−208.73M USD−204.62M USD−217.86M USD−152.1M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$104.67

28.11% downside
Past 12 months12-month forecastHigh $120Average $104.67Low $89.00

TWST peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TWST

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Innovation ETF logoARK Innovation ETFARKK
Market value
268.03M
Weight
4.04%
AUM
5.56B USD
Expense ratio
0.75%
Price / 1D
$86.21+3.53%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
223.26M
Weight
0.28%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
209.85M
Weight
1.84%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
191.8M
Weight
9.25%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$49.45+3.80%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
172.21M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
124.54M
Weight
0.07%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
82.24M
Weight
0.55%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
72.09M
Weight
0.16%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%

Continue in GoAI

Research TWST

research.disclaimer